Delta Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Delta Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$826	Hold	269	–	–	﹤0.01%	567
2025 Q4	$1.1K	Buy	269 +48	+22%	+$238	﹤0.01%	566
2025 Q3	$1.08K	Hold	221	–	–	﹤0.01%	573
2025 Q2	$1.12K	Hold	221	–	–	﹤0.01%	562
2025 Q1	$1.17K	Hold	221	–	–	﹤0.01%	566
2024 Q4	$1.49K	Buy	221 +21	+11%	+$141	﹤0.01%	570
2024 Q3	$1.32K	Hold	200	–	–	﹤0.01%	575
2024 Q2	$1.5K	Buy	+200	New	+$1.74K	﹤0.01%	575

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Delta Asset Management's RXRX Position: Q1 2026 in Review

Delta Asset Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 269 shares worth $826. The position accounts for ﹤0.01% of the portfolio, ranked #567.

Delta Asset Management first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.5K in Q2 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Delta Asset Management held 269 shares of Recursion Pharmaceuticals worth $826 as of Q1 2026.
Delta Asset Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Delta Asset Management's portfolio in Q1 2026, its #567 holding.
Delta Asset Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Delta Asset Management's Recursion Pharmaceuticals position peaked at $1.5K in Q2 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Delta Asset Management's 13F filing for Q1 2026, filed 11 May 2026.